Jeff Jones
Stock Analyst at Oppenheimer
(1.03)
# 3,808
Out of 4,984 analysts
95
Total ratings
26.67%
Success rate
-12.25%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Outperform | $50 | $32.02 | +56.15% | 1 | Sep 2, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $2.80 | +792.86% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $10.27 | +416.07% | 10 | Aug 6, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $56 → $53 | $48.78 | +8.65% | 5 | Jun 27, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $18.20 | +141.76% | 3 | Jun 24, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $20 → $15 | $8.61 | +74.22% | 3 | May 29, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $4.16 | +500.96% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $1.96 | +767.35% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $5.74 | +196.17% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $33.94 | +153.43% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $8.64 | +108.33% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.13 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.27 | +389.30% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $2.33 | +286.27% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.53 | +2,841.18% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.40 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.28 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.95 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.20 | +1,150.00% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.37 | +19,926.70% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $2.94 | +37,314.97% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Sep 2, 2025
Initiates: Outperform
Price Target: $50
Current: $32.02
Upside: +56.15%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $2.80
Upside: +792.86%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $10.27
Upside: +416.07%
Kymera Therapeutics
Jun 27, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $48.78
Upside: +8.65%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $18.20
Upside: +141.76%
Y-mAbs Therapeutics
May 29, 2025
Maintains: Outperform
Price Target: $20 → $15
Current: $8.61
Upside: +74.22%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $4.16
Upside: +500.96%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $1.96
Upside: +767.35%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $5.74
Upside: +196.17%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $33.94
Upside: +153.43%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $8.64
Upside: +108.33%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $5.13
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.27
Upside: +389.30%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.33
Upside: +286.27%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.53
Upside: +2,841.18%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $17.40
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.28
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.95
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.20
Upside: +1,150.00%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.37
Upside: +19,926.70%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $2.94
Upside: +37,314.97%